Acadia Pharmaceuticals Inc.: Morgan Stanley cuts target price to $24 from $28
ACAD•Morgan Stanley cut its target price for Acadia Pharmaceuticals Inc. to $24 from $28.
Related News
PayPay second-quarter profit drops 75% to 18.44 billion yen
PAYP•
AECOM-Jacobs venture wins consultancy work for Limerick rail upgrade
ACM•
Brazil's CSN swings to Q3 loss as iron ore prices, freight costs bite
SID•
Axsome Therapeutics: Morgan Stanley cuts target price to $223 from $249
AXSM•
Morgan Stanley cuts Exelixis target price to $57 from $60
EXEL•